Structure Therapeutics Inc. has announced the initiation of a Phase 1 clinical study for its lead oral small molecule, ACCG-2671, aimed at treating obesity. This first-in-human trial marks a significant step for the clinical-stage biopharmaceutical company based in San Francisco, which focuses on developing novel therapies for metabolic diseases.
ACCG-2671 is an amylin receptor agonist designed using Structure Therapeutics’ advanced structure-based drug discovery platform. This drug aims to leverage the known metabolic advantages of amylin biology and is formulated for once-daily oral administration. The company anticipates that this approach may enhance scalability, combinability, and patient access to treatment.
Xichen Lin, Ph.D., the Chief Scientific Officer of Structure Therapeutics, expressed optimism about the potential of amylin-based therapies. He stated, “We believe amylin-based therapies are poised to become an important next-generation component of the treatment landscape for obesity and related conditions. Powered by our differentiated GPCR structure-based drug discovery platform, we have efficiently advanced ACCG-2671 into the clinic as the industry’s most advanced oral small molecule amylin therapy.”
Promising Preclinical Data
Preclinical studies of ACCG-2671 have demonstrated promising outcomes, showcasing potent target engagement and significant weight loss as a standalone treatment. Furthermore, the drug exhibited enhanced weight reduction when administered alongside a glucagon-like-peptide receptor agonist (GLP-1 RA).
The favorable safety profile and pharmacokinetics of ACCG-2671 support its once-daily dosing regimen. This positions the drug as a potential backbone therapy, both in monotherapy and in combination with other weight loss medications. Structure Therapeutics aims to provide patients with a more effective treatment option for obesity, which continues to be a growing public health challenge.
As the Phase 1 trial progresses, the company remains focused on evaluating the safety, tolerability, and pharmacokinetics of ACCG-2671. The results from this trial will be critical in guiding the future development of this innovative therapy and its potential role in the obesity treatment landscape.
With obesity rates continuing to rise globally, the need for effective and accessible treatments is more pressing than ever. Structure Therapeutics’ efforts with ACCG-2671 could play a crucial role in addressing this ongoing health crisis.
